Innovative Holdings Alliance, Inc. is pleased to announce a Joint Venture Agreement with Synaptic OTC Sciences, a Colorado LLC.

Innovative and Synaptic have completed an Agreement that is mutually beneficial and in the best interest of our shareholders. Throughout 2015, Innovative researched many different opportunities and made significant inroads to implement our growth initiatives and contingencies.

The Company’s initial focus will be on commissioning the development of nutraceutical products and therapies aimed at providing relief for a number of diverse ailments and maladies, including but not limited to chronic pain, sleep disorders, depression, Post-Traumatic Stress Disorder and Social Anxiety Disorders.

Through this new alliance, Innovative will be providing our managerial, financial and marketing expertise for licensing a line of clinically tested, science- backed and branded medical cannabidiol and hemp products. Our incipient products will focus on chronic pain, defined as pain that persists longer than a month or two. Recent studies, published by The Institute of Medicine and The Journal of Pain to name a few, show that the total costs related to chronic pain ranged from $560 to $635 billion dollars a year. In a July 2015 NIH publication discussing Cannabinoids as medicine, “NIH-funded and other researchers are continuing to explore the possible uses of THC, CBD and other cannabinoids for medical treatment.”

“We are extremely pleased to be moving forward with exciting new products that will benefit so many people in so many ways. We expect to launch our initial line of licensed products in the coming four to six months. We feel like it is a way of building a successful Company while also giving back to so many in need,” said Chris Winter, President of Innovative. 

Innovative’s marketing materials and website are currently being updated to reflect these exciting developments regarding our new ventures.

Innovative Holdings Alliance, Inc. has embraced, as its corporate mission, a plan to acquire interests in and partner with companies that are leading edge in their respective market niches, and that have expectations of enhancing shareholder values.